Eli Lilly (NYSE:LLY) recently announced the impressive results of its SURMOUNT-5 trial, highlighting Zepbound's efficacy over ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET. Company Participants. Lucas Montarce - CFO Mike Czapar - SVP, IR. Confe ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

The stock market experienced quite a bit of volatility during President Donald Trump's first 100 days in office.

Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) ...

It has seen a steady rise from $1.28 billion in 2024 to $1.36 billion in 2025, indicating a compound annual growth rate CAGR of 6.6%. The marked growth during the historic period can be attributed to ...

The Business Research Company The Business Research Company's Huntington's Disease Global Market Report 2025 – Market Size, Trends, And For ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.